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Objectives. This study was performed to assess the efficacy,
safety and clinical consequences of abrupt cessation of qidmWil
therapy in a placebo-controlled, randomized, double-blind with-
drawal oil .
Background. Angiolensin-converting enzyme inhibitor therapy
has assumed a pivotal role in the treatment of chronic heart
failure . Quinapril hydrochloride, a uonsulfydryl angiotensin-
converting enzyme inhibitor, has shown beneficial clinical effects
in previous studies .
Methods. After 2:10 weeks of single-blind quinapril therapy,
224 patients with New York Heart Association class 11 oe III heart
failure were randomized in double-blind fashion to continue
quinapril (n = 114) or to receive placebo (n = 110) for 16 weeks .
Changes in treadmill exercise time, New York Heart Association
functional class, quality of life and symptoms of heart failure were
2-_~sessed .
Results . Patients withdrawn to placebo had a significant dete-
In patients with congestive heart failure, angiotensin-
converting enzyme inhibitor therapy lessens symptoms of
heart failure and confers a significant survival advantage
compared with placebo (1-3) and other vasodilator combi-
nations (4) . Studies have shown benefit not only in severely
symptomatic with heart failure (New York Heart Associa-
tion functional class IV) ; but also in those less functionally
impaired (1,3) . The Cooperative North Scandinavian Enala-
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duration in exercise tolerance (median change --16
9 with placebo
vs. +3 s with quinapril, p = 0 .015) . New York Heart Association
functional class (p := 0 .004) and quality of life were improved and
signs and symptoms of congestive heart failure were lessened in
those remaining on quinapril therapy compared with those receiv-
ing placebo . During double-blind treatment, 18 patients were
withdrawn from the placebo group because of worsening heart
failure compared with S patients withdrawn from quinapril
treatment (p < 0 .001) . Rather than a precipitous deterioration of
clinical status or early incidence of adverse events, withdrawal
from quinapril was associated with steady worsening of heart
failure, beginning 4 to 6 weeks after randomization to placebo .
Conclusions. Quinapril is effective and safe for maintaining
clinical stability in patients with moderate congestive heart fail-
ure. Withdrawal of quinapril from patients with heart failure
results in a slow progressive decline in clinical status .
(J Am Coll Cardiol 1993,22 :1557-63)
pril Survival Study (CONSENSUS) (1), Studies of Left
Ventricular Dysfunction (SOLVD) (3,4), Vasodilator-Heart
Failure Trial 11 (V-HeFT II) (5) and the Survival and
Ventricular Enlargement (SAVE) (6) trials have all unoer-
scored the pivotal role that angiotensin-converting enzyme
inhibitors will assume in the treatment of a growing number
of patients with chronic heart failure (7) .
Quinapril hydrochloride is a nonsulfydryl angiotensin-
converting enzyme inhibitor (8) shown to have clinical betiefit
in preliminary studies (9-11) in patients with heart failure . The
objectives of our randomized, double-blind, placebo-controlled
withdrawal study were twofold : 1) to further evaluate the
efficacy and safety of quinapril for the treatment of patients
with New Yo." Heart Association functional class 11 or III
heart failure, and 2) to determine the effect of angiotensin-
converting enzyme inhibitor withdrawal in these patients .
Methods
Trial design. Patients for this study were enrolled from 29
centers in the United States and Canada (see Appendix) . The
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Figin 1 . Study protocol . DID
-
twice daily ; CXR
-
chest roent-
gen® ; ECU electrocardiogram ;
EF
-
left ventricular ejection
fraction; NYHA 11/111
-
New York Heart Association class II or
III ; QOL
-
quality of life testing.
protocol Fig . 1 received approval from the Institutional
Review Board of each center and all patients gave informed
consent before study entry . Criteria for study eligibility
included : New York Heart Association functional class Us
slight impairment IIm moderate impairment or 111 left
ventricular ejection s35% and maximal treadmill exercise
modified Naughton times 15 min . Concurrent therapy with
beta-adrenergic blocking agents other angiotensin-
converting enzyme inhibitors vasodilators potassium-
sparing diuretic drugs calcium channel blockers fiecainide
encainide and disopyramide was not permitted during the
study . Digitalis preparations nonpotassium-sparing diuretic
drugs long- and short-acting nitrates and potassium supple-
ments were allowed throughout the study.
Eligible patients entered a single-blind quinapril dose-
titration exercise stabilization phase Fig . 1 of variable
duration minimum 10 weeks . Quinapril dosage began at
5 mg twice dailyfor week I and was increased to 10 mg twice
daily thereafter If symptomatic hypotension occurred the
dose ofquinapril or concurrent diuretic drug was decreased;
however patients unable to tolerate 2:10 mg/day ofquinapril
were withdrawn from the study. If clinically indicated the
doses ofother cardiovascular medications could be adjusted
during the 1st 8 weeks of single-blind treatment but were
maintained at a constant dose thereafter . Treadmill exercise
testing stopped for dyspnea or fatigue only was performed
weekly beginning at week 8 and was repeated until the
difference between the longest and shortest ofthree consec-
utive tests was s60 s . Patients who successfully completed
the single-blind phase were randomly assigned to a 16-week
Placebo-controlled
double-blind phase in which patients
continued with the same dose of quinapril or were with-
drawn from quinapril therapy to receive identical placebo.
To avoid unbalanced randomization patients were stratified
into two groups : those with exercise tolerance s8 min and
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those with exercise tolerance >8 min . During double-blind
therapy only one increase in diuretic drug dose for a period
of7 days was allowed . Inability to return to the baseline dose
or the need for a second increase in dose constituted a
therapeutic failure .
Efficacy end points . The primary efficacy variable was the
change in exercise duration from baseline end of single-
blind treatment to the end of double-blind treatment. Sec-
ondary end points were New York Heart Association func-
tional class quality of life assessment using the Minnesota
Living with Heart Failure Questionnaire 12 signs and
symptoms of congestive heart failure rest or exertional
dyspnea orthopnea fatigue edema and withdrawal from
therapy therapeutic failure because of worsening heart
failure .
Exercise testing. Treadmill testing was performed using a
modified Naughton protocol and was stopped for dyspnea or
fatigue only . Every attempt was made to ensure that each
exercise test was performed consistently by the patient and
administered consistently by the same personnel 13 14 .
Patients watched a video demonstrating proper exercise
testing procedures before the screening baseline and end of
study exercise test . Test administrators were provided with
standardized instructions to ensure similar techniques
words of encouragement and end point evaluations in all
centers .
Safety monitoring. A rest electrocar ''gram and chest
roentgenogram were obtained at the time of randomization
and at the end of the study . Heart rate blood pressure and
blood samples for clinical laboratory evaluation were taken
at regular intervals during the study .
Statistical analysis . Patients who were incapable of per-
forming any double-blind exercise test because they were
hospitalized for a cardiac event or were withdrawn because
of worsening congestive heart failure were assigned on a
blinded basis an exercise time of 0 s . For patients who were
withdrawn from therapy the exercise test obtained at the
time of exit from the study was designated the treadmill end
point . Only patients who performed a double-blind exercise
test or who were assigned a time of0 s were included in the
exercise time analysis n = 204 . Therefore a normal ap-
proximation to Friedman's test was performed on the me-
dian changes from baseline to the last available exercise
time . This test was performed by ranking the changes within
centers and conducting an analysis ofvariance on the ranks .
The general linear model included the main effects due to
center treatment and stratum baseline exercise time
s8
or
>8 min . All testing for a treatment effect was one-sided and
conducted at a 5% level of significance .
The number ofpatient withdrawals from the double-blind
treatment phase and changes in New York Heart Associa-
tion classification categorized as improvement no change
or deterioration were analyzed by the Cochran-Mantel-
Haenzsel procedure stratified by center to determine if
there was a significant difference between treatments. Re-
sponses to the quality of life questionnaire were summed and
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Table 1 . Clinical Character istics of 224 Patients Entering
Double-Blind Treatment
Dataare reported as mean value ± SD or number % . ACE = angiotensin-
converting enzyme inhibitor; CHF = congestive heart failure ; NYHA = New
York Heart Association ; Ilm = moderate impairment ; Its = slight impairment .
the difference in the total at baseline and the final visit was
computed for each patient who completed a questionnaire .
Treatment differences were assessed by the Wilcoxon rank-
sum test and a normal approximation to Friedman's test .
Results
Patient characteristics and disposition . Of 275 patients
who enters { the single-blind run-in phase 51 were with-
drawn : 20 for an adverse clinical event 4 for lack ofefficacy
5 for noncompliance and 22 for other reasons . The remaining
224 were randomly assigned to double-blind treatment : 114
continued to receive quinapril and 110 received placebo .
There were no significant differences in baseline clinical
characteristics between the two groups Table 1 . At the time
of study screening 66% of patients were receiving therapy
with an angiotensin-converting enzyme inhibitor. Of the 114
patients randomly assigned to continue quinapril during the
withdrawal phase 17 15% were taking 5 mg of quinapril
twice daily and the remainder were taking 10 mg twice daily .
Ofthe 110 patients assigned to receive placebo 21 19% had
been taking 5 mg of quinapril twice daily and 89 81% had
been taking 10 mg twice daily .
During double-blind treatment 36 33% of 110 patients
assigned to placebo withdrew from the study in contrast to
75
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Figure 2. Cumulative percent of patients withdrawing from double-
blind treatment because of lack of efficacy .
22 19% of 114 who continued to receive quinapril p =
0 .003 . Withdrawal for worsening heart failure Fig . 2 ac-
counted significantly for this difference .
Exercise 003erance. Exercise test data were available for
98 patients in the placebo arm and 106 in the quinapril arm
including 10 patients receiving placebo and 6 receiving
quinapril who were assigned an exercise time of 0 s . The
median change in exercise time for those 204 patients was
-16 s in the placebo group and 3 s in the quinapril group
p = 0.015 . Excluding those patients with an exercise time
of 0 s an analysis of covariance that included only patients
with double-blind exercise data showed a significant mean
difference between treatments of 42 s p = 0.003 .
Secondary efficacy results . During double-blind treat-
ment 23 patients 18 receiving placebo and 5 receiving
quinapril p < 0.001 were declared to have had a therapeutic
failure and were withdrawn from the study Fig . 2 . Most
therapeutic failures in the placebo arm occurred between the
5th and 12th week of double-blind therapy . Therapeutic
failure occurred more frequently in placebo-treated patients
with a left ventricular ejection fraction <30% than in those
with an ejection fraction 2:30% . Likewise therapeutic fail-
ure was more frequent in patients in New York Heart
Association functional class III than in patients who were
less impaired . At least one increase in diuretic dose was
required in 28 patients in the placebo group compared with
13 in the quinapril-treated group .
New York Heart Association functional class information
was available for 107 patients treated with placebo and for
111 who continued to receive quinapril Fig. 3 . Although
most patients remained in the same New York Heart Asso-
ciation functional class during the withdrawal phase the
condition of 8% of placebo-treated patients and 13% of
quinapril-treated patients improved whereas that of 18% of
placebo-treated patients and 9% of quinapril-treated patients
deteriorated p = 0.004 .
Quality of life scores for 90 patients treated with placebo
and 89 who continued to receive quinapril were available
for
analysis. Patients who were withdrawn from quinapril ther-
Characteristic
Placebo
In = 110
Quinapril
I = 1141
Total
n = 224
Gender no. R
Male 95 86 95 81 187 83
Female 15
14 22 19 37 11
Age y
60
±
11 61 t 10 61 ± 11
Weight kg 82 ± 16 81 ± 16
82 ± 16
Duration of CHF yr 4±4
4±4 4±4
Etiology of CHF
Ischemic 65 59 76 67 14] 63
Nouischemic 45 41 37 32 82 37
Not specified 0
1 1 1 < 1
NYHA class
Its
23 21 21 18 44 20
Ilm 51 46 60 53 111 50
[if 35 32
3] 27
66
29
Not specified 1 1 1 1 2
Fjcct ;on fraction
%
25 t 7 25 ± 7 25
Range 5-35 10-35 5-35
Biochemistry
Serum sodium mmoilliter 139 ± 4 139±3 139±4
Creatinine pmoffliler 119 ± 35
116 ± 35 118 ± 35
Urea mmoUliter 7 .4
±
3 .2 7 .8 ± 3 .9 7 .6 ± 3 .6
Medications
Digoxin use no . [%J
83
75
90 79 173 77
ACE inhibitor use no . 66 60 81 71 147 66
Mean furosemide
dose
mg 72 ± 71 68 ± 53 70 ± 62
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apy reported that their quality of life had not changed
median change 0 whereas those who continued to receive
quinapril indicated that their quality of life had
improved
slightly median change -2 p = 0.032 . Signs and symptoms
of congestive heart failure were evaluated at every study
visit. A greater percent of patients who were withdrawn
from quinapril had some degree of deterioration in signs and
symptoms of congestive heart failure .
Adverse events Table 2 . Withdrawal from the study
occurred because of an adverse event in 20 patients during
the single-blind phase sudden death in 9 light-headedness/
hypotension in 4 worsening heart failure in 1 hyperkalemia
in I and other event in 5 . During double-blind therapy five
patients receiving placebo were withdrawn bec cruse of an
adverse event sudden death cardiogenic shock cough
hypertension and new onset atrial fibrillation in one patient
each . During double-blind therapy seven patients receiving
quinapril were withdrawn because of an adverse event
sudden death myocardial infarction syncope renal dys-
Tam 2. Side Effects Reported During Single- and
Double-Blind Treatment
No significant differences
between placebo and
double-blind quinapril.
Data are reported
as number % of patients. ALT =
alaninc aminotransfer-
ase.
better
worse
!ACC Vol . 22 No
.
6
November 15 . 1993 : 1 55
7
-03
Figure 3 . Secondary end point vari-
ables . NYHA = New York Heart As-
sociation functional class
.
function hypotension hyponatremia and incessant cough
in one patient each . Minor side effects of therapy such as
cough taste disturbance light-headedness and gastrointes-
tinal upset were uncommon and occurred with equal fre-
quency in the two groups during double-blind treatment .
Discussion
In the current study quinapril was found to have benefi-
cial effects on exercise tolerance functional capacity and the
clinical course of heart failure .
Pharmacology of quinapril. After oral administration .
50% to 70% of quinapril hydrochloride s rapidly absorbed
from the gastrointestinal tract and hydrolyzed to its major
active metabolite quinaprilat 8 15 a potent inhibitor of
plasma angiotensin-converting enzyme. Peak quinaprilat
plasma concentrations are reached approximately 2 h after
oral administration and excretion is primarily in urine 61%
and bile 37% . Quinaprilat also has high affinity for tissue
angiotensin-converting enzyme including cardiac angiotensin-
converting enzyme more so than other angiotensin-converting
enzyme inhibitors used for the treatment of congestive heart
failure 16-19 .
Prior studies in heart failure . The short- and long-term
hemodynamic effects of quinapril have been studied in
patients with New York Heart Association class III or IV
heart failure 9 10 . Significant favorable effects on systemic
vascular resistance pulmonary capillary wedge pressure and
cardiac index were maintained . In a double-blind placebo-
controlled study 11 of patients with New York Heart
Association functional class II or III heart failure receiving
constant digitalis or diuretic drugs or both a dose-related
increase in exercise time was noted . However no additional
benefit was observed with 40 mg/day compared with
20 mg/day . New York Heart Association functional class
improved in 70% of patients in class III and 28% of patients
in class II .
Trial design . The current study sought to determine the
effect of withdrawing an active treatment . Although the
Side Effect
Single-Blind
Quinaprit
Placebo
Double-Blind
Quinapril
Hypotension 80 0
0
Dizziness 140 1 1 0
Taste disturbance
1 <I 0 0
Dyspepsia 2 2
30
1
1
Nausealvomiting 130 2 2
30
Diarrka 8 3
40 30
Cough
19 7 40
7 6
Skin rash
30 0 1
1
Impotence
1 KI 0
2 2
6 2 2 2 11 10
Increase in creatinine 20 1 1
1 l
Increase in ALT
20 1 1 0
Hyperkalmia
0
0 1 1
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results of the SOLVI trial 3 4 were not available before
designing the current study the high 661 6 rate ofangiotensin-
converting enzyme inhibitor use in the study cohort empha-
sized the general clinical sentiment that these agents were
efficacious even for those with mild to moderate heart
failure . The withdrawal design of this study had the advan-
tage ofminimizing placebo exposure during a placebo run-in
phase and subsequently for those declared to have a thera-
peutic failure . Recently other trials 20 21 of heart failure
therapy most notably digoxin have employed a withdrawal
design to test drug efficacy .
Theoretically studies using a withdrawal design should
result in treatment differences similar to those of trials
randomizing to active treatment or placebo after a placebo
run-in phase . Initiation of an active therapy after placebo
run-in should result in significant progressive improvement
whereas patients continuing to receive placebo should expe-
rience continued slight deterioration or no improvement .
With the current design continued active therapy after a
prolonged single-blind phase of therapy would be expected
to result in stabilization of heart failure and perhaps slight
continued improvement and withdrawal of therapy would
be expected to result in progressive deterioration as was
observed . Indeed a withdrawal study with a long single-
blind active treatment phase as in this study may result in
a significant bias in favor of the placebo arm . All patients
during single-blind therapy were maintained on optimal
therapy with frequent and attentive follow-up of heart fail-
ure which may in itself have resulted in significant physical
conditioning 22 23 whose effects may have carried over
into the withdrawal phase . A potential limitation ofthe study
relates to the analysis of exercise times in those patients
withdrawn from treatment and unable to exercise because of
worsening heart failure . To deal with this issue it was
believed that the most appropriate analysis would include
those patients assign an exercise time of 0 s to them and
evaluate the median change in exercise time as described . A
post-hoc evaluation analysis of covariance that included
only patients with double-blind exercise data showed that
such an analysis did not affect the outcome and a significant
mean difference between treatments of 42 s was retained
p = 0.003 .
Efficacy of therapy . All measures of drug efficacy favored
quinapril therapy . Treadmill exercise duration continued to
improve with quinapril despite stabilization of heart failure
during 10 to 12 weeks of single-blind therapy . In contrast
exercise duration during placebo withdrawal decreased sig-
nificantly resulting in a median difference of 19 s between
the two groups . Although a statistically significant difference
between the two groups was noted a training effect during
single-blind therapy may have carried over significantly into
the double-blind phase thereby minimizing the difference
observed . A study of longerduration may have magnified the
difference in treadmill performance .
Most striking was withdrawal from therapy because of
lack of efficacy. Only 4.4% of patients continuing in the
PFLUGFELDER ET AL .
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quinapril treatment arm withdrew as a result of worsening
heart failure compared with 16.4% of those receiving pla-
cebo. Attrition from the placebo arari was progressive
throughout and the withdrawal curves continued to diverge
at the end of the study Fig . 2 . Those with the most
significantly reduced functional capacity and those with the
most depressed left ventricular function had the greatest
withdrawal rates in the placebo arm . These observations
serve to identify those persons who are likely to benefit most
from therapy with angiotensin-converting enzyme inhibitors .
Other secondary end point variables such as New York
Heart Association functional class and heart failure symp-
toms also supported the efficacy of quinapril .
Withdrawal from angiotensin-converting enzyme inhibitor
therapy . As angiotensin-converting enzyme inhibitors be-
come more widely used for the treatment of heart failure
concern has arisen about the potential for rebound wors-
ening of clinical status after withdrawal from therapy for
example physician-initiated withdrawal or patient noncom-
pliance Konstam et al . 24 observed a rapid increase in left
ventricular chamber size and a high incidence of major
adverse events within 3 weeks after abrupt cessation of
treatment with enalapril although these observations were
made in a very small sample of patients n = 22 . In another
small sample of patients n = 5 with severe heart failure
Nicholls et al . 25 documented the clinical hemodynamic
and hormonal responses after short-term withdrawal of
captopril . Clinical variables and left ventricular function
were not altered after 6 days of withdrawal ; however
significant elevations in heart rate blood pressure angioten-
sin II and plasma norepinephrine were observed .
In the current study rather than a precipitous deteriora-
tion of clinical status or a high early incidence of adverse
events withdrawal from quinapril was associated with a
gradual worsening of heart failure beginning 4 to 6 weeks
after randomization to placebo . Although plasma and tissue
angiotensin-converting enzyme inhibition is short-lived after
treatment is stopped patients in this study may have bene-
fited from optimal treatment of heart failure during single-
blind treatment as well as carryover effects of physical
conditioning on peripheral vascular and skeletal muscle
adaptations to heart failure 22 23 .
Safety and tolerability . Quinapril was well tolerated and
the side effect profile in the current study was similar to that
reported for other angiotensin-converting
enzyme inhibitors
during treatment of heart failure 26-29 .
Conclusions. Quinapril is effective fer maintaining clini-
cal stability in patients with moderate congestive heart
failure . Abrupt withdrawal of quinapril from patients with
heart failure results in a slow progressive
decline in clinical
status .
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Appendix
The Quinapril Heart Failure
Trial Investigators
Mario E . Mota MD Maureen Criasia
RN Cardiology Physician Inc .
Lynn
MA
Alexander M. M. Shepherd MD Peter A .
Carberry MD University of
Texas
Health Science Center San Antonio TX
Thomas 0. Paul Jr . MD Amanda Vick RN
Brookwood Cardiology
Associates Birmingham AL
NaM El-Sherif MD ; Mahshid Assadi MD Saied Menheji Brooklyn
VA
Hospital n NY
William Bowden MD Catherine Russell BSN Cardiology Associates of
Santa Rosa Santa Rose CA
John C . Bailey MD Karl Berron MSN Methodist Hospital Indianap-
olis IN
Harry Coffer MD Barbara Stone MSN Nisus Research Inc .
Petoskey MI
David Waters MD Joanne Marquis RN Montreal Heart Institute
Montreal Quebec Canada
Melvin J . Tonkon MD Catherine Fox BS Cardiology Associates
Medical Group Anaheim CA
H J. Blair MD Mark maaek BS Saginaw. MI
Robert Marshall MD Violet- Quiazon RN Martinez VA Medical
Center Martinez CA
0 . B . John Mancini MD Judy Richards RN VA Medical Center Ann
Arbor MI
T. A. Don Michael MD Chris Whitlock RN Central Cardiology
Medical Clinic Bakersfield CA
William J . Bream MD Debbie
Summers RN
Buffalo
Cardiology Asso-
ciates Williamsville
NY
Michael Rotman MD Euna Maynard
RN Austin TX
Michael
Baird MD Barbara Aubrey RN MS
Heart Institute Ottawa
Civic
Hospital Ottawa Ontario Canada
Peter
Pflugfelder MD William J . Kostuk MD iota Kennedy . RN
University Hospital London Ontario Canada
William B . Smith MD Juanita Young RN New Orleans LA
Richard Schott MD Kim Moretti RN Sacred Heart Medical Office
Bldg Chester PA
Stephen ?.inner MD Lore Frighetti RN Clinical Physiology Associ-
ates Ft . Myers FL
JohnC . Somberg MD Michele Staben RN North Chicago VA Medical
Center North Chicago IL
Robert
Zoble MD Jan Btewington RN J. A . Haley VA Hospital
To FL
Koonlawe
Nademenec MD Jill DiPasquale RN Cardiovascular Re-
search Denver CO
C
V.
Reddy MD Tap Kwan
MD SUNY Downstate Medical Center
°n NY
Steven N ' MD B
Bennett BSN MA VA Medical Center
Woshin8ton DC
AWlia
J.
Argenal MD Gerry Franco RN Contra Costa
Cardiology
Concord CA
Bruce K.
Jackson MD Peggy Walker RN
Cardiology Associates
R
h CA
JamesC w MD Linda
Stollings RN Selma Medical Associates
Winchester VA
David Chinoy MD
Cynthia Buda RN BSN Jacksonville Cardiovascu.
lar Clinic
.
J v lle FL
Nicholas
Kerin MD Kathy Faitcl RN Sinai Hospital Detroit M1
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